EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR


 

EQS-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Study
Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR

25-Nov-2022 / 15:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Berlin, 25 November 2022. PENTIXAPHARM GmbH, a 100% subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), received green light from the European Medicines Agency (EMA) to conduct a phase III registration study in patients suffering from various forms of Non-Hodgkin-Lymphomas. Following several rounds of scientific advice, the EMA Committee for Medicinal Products for Human Use (CHMP) endorsed a study design presented by PENTIXAPHARM’s management, which envisions treating up to 500 lymphoma patients with the Gallium-68 based radiotracer PENTIXAFOR in about 30 participating European clinics. In its endorsement the CHMP adopted the advice given by the EMA Scientific Advice Working Party, a multidisciplinary group, which comprises delegates from several national European Health Agencies, members of the Committee for Orphan Medicinal Products, the Paediatric Committee, the Committee for Advanced Therapies and the Pharmacovigilance Risk Assessment Committee. The first treatments with PENTIXAFOR are expected to start in the first half of 2023, subject to approval by national health authorities.

The Executive Board expects to have completed the clinical trials and approval of PENTIXAFOR by the end of 2025 and estimates development costs of EUR 50 million, which will initially be capitalized in the balance sheet and thus not be recognized in the income statement. In addition to the diagnostic agent, Eckert & Ziegler is also developing radiotherapeutics for several hematological indications based on CXCR4 peptides. The Group acquired the global property rights to the CXCR4 receptor addressing agents from the patent licensing office of the Technical University of Munich.

For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected]; www.ezag.com 

25-Nov-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1497999

 
End of Announcement EQS News Service

1497999  25-Nov-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1497999&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 137,94 138,63 168,71 178,49 176,14 180,44 225,00
EBITDA1,2 24,97 26,62 32,14 43,13 44,64 57,04 61,00
EBITDA-Marge3 18,10 19,20 19,05 24,16 25,34 31,61 27,11
EBIT1,4 16,23 17,97 23,39 32,06 33,69 47,45 51,00
EBIT-Marge5 11,77 12,96 13,86 17,96 19,13 26,30 22,67
Jahresüberschuss1 9,79 15,12 16,89 22,48 23,11 34,66 29,90
Netto-Marge6 7,10 10,91 10,01 12,59 13,12 19,21 13,29
Cashflow1,7 19,83 26,83 21,21 40,43 36,79 33,86 32,00
Ergebnis je Aktie8 0,45 0,70 0,78 1,07 1,11 1,66 1,40
Dividende8 0,17 0,20 0,30 0,42 0,45 0,50 0,25
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 54,000 Halten 1.143,28
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
34,39 25,13 1,37 61,16
KBV KCV KUV EV/EBITDA
6,07 33,77 5,08 18,91
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
Hauptversammlung
0,25 0,30 0,46 07.06.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.05.2023 10.08.2023 14.11.2023 30.03.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
8,96% 26,40% 16,38% -27,22%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei EQS abrufen


Medtech , 565970 , EUZ , XETR:EUZ